In this report, the EMEA Primary Antibodies Market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025.
Primary antibodies are immunoglobulins that bind to a specific antigen of interest and are typically unconjugated. These antibodies find application in detection of biomarkers for diseases such as cancer, diabetes, Parkinson’s, and Alzheimer’s disease. Depending on the source of development, primary antibodies can be monoclonal or polyclonal in type.
Increasing prevalence of cancer is expected to boost growth of EMEA primary antibodies market over the forecast period. For instance, according to the World Health Organization, the number of new cancer cases diagnosed per year in Africa is expected to grow from over 1 million in 2018 to over 2.1 million in 2040. Moreover, R&D breast cancer therapy is also expected to aid in growth of the market. For instance, in December 2018, researchers from Manisa Celal Bayar University, in the study ‘Cyclophosphamide Inhibits PI3K/AKT/mTOR Signaling Pathway in Mice Kidneys’ stained the tissues via indirect immunohistochemistry with PI3K, AKT and mTOR primary antibodies in order to show the effect of cyclophosphamide in kidney tissue.
High incidence of diabetes is expected to contribute to growth of EMEA primary antibodies market over the forecast period. For instance, according to the International Diabetes Federation, the number of people with diabetes in Africa is expected to increase in 143% by 2045 compared to 2019. Moreover, increasing investment in cancer detection is also expected to aid in growth of the market. For instance, in September 2019, Kheiron Medical Technologies, announced a US$ 22 million Series A round for early breast cancer detection for women worldwide.
Major players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in February 2020, StressMarq Biosciences, a supplier of primary antibodies, antibody conjugates, proteins, immunoassay kits and small molecules, collaborated with, Cellectricon, a company focused on advancing drug discovery, for the development of next-generation reagents and assays for neurodegenerative disease research.
Major players in the market are also focused on product development to expand their product portfolio. For instance, In September 2019, Biocare Medical, LLC launched a new mouse monoclonal antibody, p16 INK4a, for in vitro diagnostic use in the qualitative identification of the p16 INK4a protein by immunohistochemistry in formalin-fixed paraffin-embedded human tissues.
Key Takeaways
- Increasing prevalence of cancer is expected to augment growth of EMEA primary antibodies market over the forecast period
- Investment in cancer detection is also expected to aid in growth of the market
- Major players operating in EMEA primary antibodies market include, Abcam, BD, Santa Cruz Biotechnology, Sigma Aldrich Corporation, Thermo Fisher Scientific, Bio-Rad, R&D Systems, MBL, CST, Merk, Novus Biologicals, PeproTech, Cayman, AbMax Biotechnology, MABTech, KPL, and Abnova
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Primary Antibodies for these regions, from 2014 to 2025 (forecast)
➣ Europe: Germany, France, UK, Russia, Italy and Benelux;
➣ Middle East: Saudi Arabia, Israel, UAE and Iran;
➣ Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Primary Antibodies market competition by top manufacturers/players, with Primary Antibodies sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
➣ Abcam
➣ BD
➣ Santa Cruz Biotechnology
➣ Sigma Aldrich Corporation
➣ Thermo Fisher Scientific
➣ Bio-Rad
➣ R&D Systems
➣ MBL
➣ CST
➣ Merk
➣ Novus Biologicals
➣ PeproTech
➣ Cayman
➣ AbMax Biotechnology
➣ MABTech
➣ KPL
➣ Abnova
On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
➣ Human
➣ Animal
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Pcs), market share and growth rate of Primary Antibodies for each application, including
➣ ELISA
➣ Western Blot
➣ Immunostaining
➣ Immunohistochemistry
➣ Immunocytochemistry
➣ Other
**NOTE: If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
EMEA (Europe, Middle East and Africa) Primary Antibodies Market Report 2019
1 Primary Antibodies Overview
1.1 Product Overview and Scope of Primary Antibodies
1.2 Classification of Primary Antibodies
1.2.1 EMEA Primary Antibodies Market Size (Sales) Comparison by Type (2014-2025)
1.2.2 EMEA Primary Antibodies Market Size (Sales) Market Share by Type (Product Category) in 2018
1.2.3 Human
1.2.4 Animal
1.3 EMEA Primary Antibodies Market by Application/End Users
1.3.1 EMEA Primary Antibodies Sales (Volume) and Market Share Comparison by Application (2014-2025
1.3.2 ELISA
1.3.3 Western Blot
1.3.4 Immunostaining
1.3.5 Immunohistochemistry
1.3.6 Immunocytochemistry
1.3.7 Other
1.4 EMEA Primary Antibodies Market by Region
1.4.1 EMEA Primary Antibodies Market Size (Value) Comparison by Region (2014-2025)
1.4.2 Europe Status and Prospect (2014-2025)
1.4.3 Middle East Status and Prospect (2014-2025)
1.4.4 Africa Status and Prospect (2014-2025)
1.5 EMEA Market Size (Value and Volume) of Primary Antibodies (2014-2025)
1.5.1 EMEA Primary Antibodies Sales and Growth Rate (2014-2025)
1.5.2 EMEA Primary Antibodies Revenue and Growth Rate (2014-2025)
2 EMEA Primary Antibodies Competition by Manufacturers/Players/Suppliers, Region, Type and Application
2.1 EMEA Primary Antibodies Market Competition by Players/Manufacturers
2.1.1 EMEA Primary Antibodies Sales Volume and Market Share of Major Players (2014-2019)
2.1.2 EMEA Primary Antibodies Revenue and Share by Players (2014-2019)
2.1.3 EMEA Primary Antibodies Sale Price by Players (2014-2019)
2.2 EMEA Primary Antibodies (Volume and Value) by Type/Product Category
2.2.1 EMEA Primary Antibodies Sales and Market Share by Type (2014-2019)
2.2.2 EMEA Primary Antibodies Revenue and Market Share by Type (2014-2019)
2.2.3 EMEA Primary Antibodies Sale Price by Type (2014-2019)
2.3 EMEA Primary Antibodies (Volume) by Application
2.4 EMEA Primary Antibodies (Volume and Value) by Region
2.4.1 EMEA Primary Antibodies Sales and Market Share by Region (2014-2019)
2.4.2 EMEA Primary Antibodies Revenue and Market Share by Region (2014-2019)
2.4.3 EMEA Primary Antibodies Sales Price by Region (2014-2019)
3 Europe Primary Antibodies (Volume, Value and Sales Price), by Players, Countries, Type and Application
3.1 Europe Primary Antibodies Sales and Value (2014-2019)
3.1.1 Europe Primary Antibodies Sales Volume and Growth Rate (2014-2019)
3.1.2 Europe Primary Antibodies Revenue and Growth Rate (2014-2019)
3.2 Europe Primary Antibodies Sales and Market Share by Type
3.3 Europe Primary Antibodies Sales and Market Share by Application
3.4 Europe Primary Antibodies Sales Volume and Value (Revenue) by Countries
3.4.1 Europe Primary Antibodies Sales Volume by Countries (2014-2019)
3.4.2 Europe Primary Antibodies Revenue by Countries (2014-2019)
3.4.3 Germany Primary Antibodies Sales and Growth Rate (2014-2019)
3.4.4 France Primary Antibodies Sales and Growth Rate (2014-2019)
3.4.5 UK Primary Antibodies Sales and Growth Rate (2014-2019)
3.4.6 Russia Primary Antibodies Sales and Growth Rate (2014-2019)
3.4.7 Italy Primary Antibodies Sales and Growth Rate (2014-2019)
3.4.8 Benelux Primary Antibodies Sales and Growth Rate (2014-2019)
4 Middle East Primary Antibodies (Volume, Value and Sales Price), by Region, Type and Application
4.1 Middle East Primary Antibodies Sales and Value (2014-2019)
4.1.1 Middle East Primary Antibodies Sales Volume and Growth Rate (2014-2019)
4.1.2 Middle East Primary Antibodies Revenue and Growth Rate (2014-2019)
4.2 Middle East Primary Antibodies Sales and Market Share by Type
4.3 Middle East Primary Antibodies Sales and Market Share by Application
4.4 Middle East Primary Antibodies Sales Volume and Value (Revenue) by Countries
4.4.1 Middle East Primary Antibodies Sales Volume by Countries (2014-2019)
4.4.2 Middle East Primary Antibodies Revenue by Countries (2014-2019)
4.4.3 Saudi Arabia Primary Antibodies Sales and Growth Rate (2014-2019)
4.4.4 Israel Primary Antibodies Sales and Growth Rate (2014-2019)
4.4.5 UAE Primary Antibodies Sales and Growth Rate (2014-2019)
4.4.6 Iran Primary Antibodies Sales and Growth Rate (2014-2019)
5 Africa Primary Antibodies (Volume, Value and Sales Price) by Players, Countries, Type and Application
5.1 Africa Primary Antibodies Sales and Value (2014-2019)
5.1.1 Africa Primary Antibodies Sales Volume and Growth Rate (2014-2019)
5.1.2 Africa Primary Antibodies Revenue and Growth Rate (2014-2019)
5.2 Africa Primary Antibodies Sales and Market Share by Type
5.3 Africa Primary Antibodies Sales and Market Share by Application
5.4 Africa Primary Antibodies Sales Volume and Value (Revenue) by Countries
5.4.1 Africa Primary Antibodies Sales Volume by Countries (2014-2019)
5.4.2 Africa Primary Antibodies Revenue by Countries (2014-2019)
5.4.3 South Africa Primary Antibodies Sales and Growth Rate (2014-2019)
5.4.4 Nigeria Primary Antibodies Sales and Growth Rate (2014-2019)
5.4.5 Egypt Primary Antibodies Sales and Growth Rate (2014-2019)
5.4.6 Algeria Primary Antibodies Sales and Growth Rate (2014-2019)
6 EMEA Primary Antibodies Manufacturers/Players Profiles and Sales Data
6.1 Abcam
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Primary Antibodies Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Abcam Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.1.4 Main Business/Business Overview
6.2 BD
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Primary Antibodies Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 BD Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.2.4 Main Business/Business Overview
6.3 Santa Cruz Biotechnology
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Primary Antibodies Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Santa Cruz Biotechnology Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.3.4 Main Business/Business Overview
6.4 Sigma Aldrich Corporation
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Primary Antibodies Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Sigma Aldrich Corporation Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.4.4 Main Business/Business Overview
6.5 Thermo Fisher Scientific
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Primary Antibodies Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Thermo Fisher Scientific Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.5.4 Main Business/Business Overview
6.6 Bio-Rad
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Primary Antibodies Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Bio-Rad Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.6.4 Main Business/Business Overview
6.7 R&D Systems
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Primary Antibodies Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 R&D Systems Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.7.4 Main Business/Business Overview
6.8 MBL
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 Primary Antibodies Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 MBL Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.8.4 Main Business/Business Overview
6.9 CST
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Primary Antibodies Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 CST Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.9.4 Main Business/Business Overview
6.10 Merk
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 Primary Antibodies Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Merk Primary Antibodies Sales, Revenue, Price and Gross Margin (2014-2019)
6.10.4 Main Business/Business Overview
6.11 Novus Biologicals
6.12 PeproTech
6.13 Cayman
6.14 AbMax Biotechnology
6.15 MABTech
6.16 KPL
6.17 Abnova
7 Primary Antibodies Manufacturing Cost Analysis
7.1 Primary Antibodies Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Primary Antibodies
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Primary Antibodies Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Primary Antibodies Major Manufacturers in 2018
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 EMEA Primary Antibodies Market Forecast (2019-2025)
11.1 EMEA Primary Antibodies Sales, Revenue and Price Forecast (2019-2025)
11.1.1 EMEA Primary Antibodies Sales and Growth Rate Forecast (2019-2025)
11.1.2 EMEA Primary Antibodies Revenue and Growth Rate Forecast (2019-2025)
11.1.3 EMEA Primary Antibodies Price and Trend Forecast (2019-2025)
11.2 EMEA Primary Antibodies Sales, Revenue and Growth Rate Forecast by Region (2019-2025)
11.3 Europe Primary Antibodies Sales, Revenue and Growth Rate Forecast by Region (2019-2025)
11.4 Middle Eastt Primary Antibodies Sales, Revenue and Growth Rate Forecast by Region (2019-2025)
11.5 Africa Primary Antibodies Sales, Revenue and Growth Rate Forecast by Region (2019-2025)
11.6 EMEA Primary Antibodies Sales Forecast by Type (2019-2025)
11.7 EMEA Primary Antibodies Sales Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
Request Discount 
Inquire Before Buy
